Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

被引：1

作者：

Boegemann, Martin

Bedke, Jens

Schostak, Martin

Welslau, Manfred

Hering-Schubert, Christiane

Wolf, Thomas

Schleicher, Jan

Petzold, Alexander

Doehn, Christian

Gruellich, Carsten

Gruenwald, Viktor

Steiner, Thomas

Ehness, Rainer

Klein, Dunja

Medinger, Tanja

Goebell, Peter-Juergen

机构：

[1] Univ Munster, Med Ctr, Munster, Germany

[2] Univ Tubingen, Dept Urol, Tubingen, Germany

[3] Univ Magdeburg, Magdeburg, Germany

[4] Hematol Oncol Practice, Aschaffenburg, Germany

[5] St Georg Klinikum Eisenach, Eisenach, Germany

[6] Hamatol Intern Onkol, Gemeinschaftspraxis Hamatol Onkol, Dresden, Germany

[7] Katharinen Hosp, Stuttgart, Germany

[8] GP Dres, Wilke Wagner Petzoldt Hamatol Onkol, Furth, Germany

[9] Urologikum Lubeck, Lubeck, Germany

[10] Heidelberg Univ, Heidelberg, Germany

[11] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[12] Helios Klinikum Erfurt, Klin Urol, Erfurt, Germany

[13] Novartis Pharma GmbH, Nurnberg, Germany

[14] IOMEDICO AG, Mol Med, Freiburg, Germany

[15] IOMEDICO AG, Stat, Freiburg, Germany

[16] Univ Hosp Erlangen, Erlangen, Germany

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4584

引用

页数：1